J&J Erleada improves prostate cancer outcomes

Johnson & Johnson>>>'s prostate cancer drug, Apalutamide>>>, in combination with hormone-blocking therapy, has shown significant success in late-stage clinical trials. The study, presented at the American Society of Clinical Oncology>>> meeting, revealed that the regimen improved the chances of eliminating cancer and reduced the risk of disease progression or death by up to 29% in men with high-risk localized or locally advanced prostate cancer. This data, described as 'paradigm changing' by lead researcher Dr. Mary-Ellen Taplin>>> from Dana–Farber Cancer Institute>>>, suggests a potential shift in the standard of care for these patients. Johnson & Johnson>>> plans to seek global regulatory approvals to expand Apalutamide>>>'s use to earlier stages of the disease.